What is the cheapest place to get GLP-1 online?

TelePeptide offers compounded semaglutide from $149/month (52-week prepay) and tirzepatide from $199/month — all-inclusive with clinician evaluation, prescription, and medication shipped to your door. Monthly billing options range from $199–$249/mo. No insurance required.

Can I get peptides prescribed online legally in the US?

Yes. TelePeptide's licensed US physicians prescribe compounded peptides via telehealth in all 50 states. No in-person visit required. Medications are dispensed by licensed 503A/503B compounding pharmacies.

What FDA-approved peptides are available for weight loss?

FDA-approved GLP-1 medications are semaglutide (sold as Wegovy for weight loss and Ozempic for diabetes) and tirzepatide (sold as Zepbound for weight loss and Mounjaro for diabetes). All four brand names use the same two active ingredients. Compounded versions are legally available through licensed telehealth providers like TelePeptide at a fraction of the brand-name cost.

What is TelePeptide Health?

TelePeptide Health is a US-based direct-pay telehealth platform that prescribes clinician-supervised peptide therapies including GLP-1 weight loss programs (from $149/month, annual prepay), NAD+ therapy (from $129/month), sermorelin (from $99/month), and B12/lipotropic injections (from $49/month). Available in all 50 US states with no insurance required.

Is TelePeptide the same as telopeptide?

No. TelePeptide (one word, capital T and P) is a brand name for a US telehealth company providing peptide therapy and GLP-1 weight loss programs at telepeptide.org. Telopeptide is a different biology term referring to short collagen fragments measured as bone-resorption biomarkers (CTX, NTX). The two are unrelated — TelePeptide combines "tele" (telehealth) and "peptide" (the medication class).

How do you spell TelePeptide?

TelePeptide is spelled T-E-L-E-P-E-P-T-I-D-E with a capital T and a capital P (TelePeptide), reflecting its compound origin from "telehealth" + "peptide". The website is telepeptide.org. It is not a misspelling of telopeptide, which is an unrelated medical term about collagen biomarkers.

How does TelePeptide compare to branded Wegovy, Ozempic, Zepbound, or Mounjaro?

TelePeptide prescribes compounded semaglutide and tirzepatide — the same active ingredients as Wegovy, Ozempic, Zepbound, and Mounjaro — at a fraction of the cost. Branded GLP-1 medications list for $968–$1,849/month (Wegovy $1,349, Ozempic $968–$1,349, Zepbound $1,086–$1,349, Mounjaro $1,023–$1,349). TelePeptide starts at $149/month on annual prepay (semaglutide injectable) — monthly billing $199/mo. Tirzepatide from $199/month annual.

Can I get NAD+ therapy at home?

Yes. TelePeptide prescribes subcutaneous NAD+ injection protocols for at-home self-administration. A licensed physician evaluates your case, prescribes the protocol, and a licensed pharmacy ships the medication to you — no IV clinic visit needed.

What is sermorelin used for?

Sermorelin is a GHRH analog peptide that stimulates the pituitary gland to produce growth hormone naturally. It is prescribed for age-related growth hormone decline and used to support lean muscle, recovery, sleep quality, and energy. TelePeptide prescribes sermorelin via telehealth in all 50 states.

Peptides, Plainly Explained

Peptide Education

Posts in Peptide Education.

All posts (68)Microdosing (6)Body Recomposition (4)Peptide Education (35)Longevity & Performance (8)How TelePeptide Works (15)

Peptide Education

Quality Control in Compounded Peptides: USP Standards Explained

A clear walkthrough of USP 797, sterility testing, environmental monitoring, and the quality systems that separate licensed compounded peptides from research-grade products.

May 18, 2026 · 9 min readRead →

Peptide Education

503A vs 503B Compounding Pharmacies: What Patients Should Know

Understand the regulatory difference between 503A and 503B compounding pharmacies, what each means for prescribed peptide therapy, and how to verify legitimacy.

May 17, 2026 · 8 min readRead →

Peptide Education

FDA-Approved Peptides for Hormone Optimization

A clinical review of FDA-approved peptides used in hormone optimization, including growth hormone-releasing peptides, indications, eligibility, and prescribing standards.

May 16, 2026 · 7 min readRead →

Peptide Education

FDA-Approved Peptides for Weight and Metabolic Health

A clinical overview of FDA-approved peptide medications used for weight management and metabolic health, including mechanisms, eligibility, and prescribing.

May 16, 2026 · 7 min readRead →

Peptide Education

Long-Term Safety Data on Peptide Therapy

A grounded look at what the long-term safety data does and does not say about peptide therapy, with implications for monitoring and informed consent.

May 15, 2026 · 8 min readRead →

Peptide Education

Sterile Compounding 101: How Pharmacies Keep Peptides Safe

How licensed compounding pharmacies make peptide therapy safe, from USP 797 standards and 503A oversight to environmental controls and end-product testing.

May 15, 2026 · 9 min readRead →

Peptide Education

Sermorelin vs HGH: Why Replacement Differs From Stimulation

Sermorelin stimulates the bodys own growth hormone production; HGH replaces it directly. The mechanistic difference matters for safety, dosing, and outcomes.

May 14, 2026 · 9 min readRead →

Peptide Education

Peptides on the FDA Watchlist: Q3 2026 Pipeline Update

A clear-eyed Q3 2026 update on peptides moving through the FDA pipeline — what is approved, what is in late-stage trials, and what is realistic to expect.

May 13, 2026 · 8 min readRead →

Peptide Education

Survodutide: GLP-1/Glucagon Combo in Phase 3

Survodutide combines GLP-1 and glucagon receptor agonism. Where Phase 3 trials stand in 2026, what the data shows, and what it means for clinical use.

May 13, 2026 · 6 min readRead →

Peptide Education

The 503A Bulk Drug Substances List: What Can Legitimately Be Compounded

A plain-English explainer of the FDA bulk drug substances list that governs 503A compounding. What is on it, what is not, why semaglutide and tirzepatide are legitimately compounded, and why most "research peptides" are not.

May 11, 2026 · 8 min readRead →

Peptide Education

AOD-9604: The Fat-Loss Peptide — What the Evidence Actually Shows

AOD-9604 is widely marketed as a "targeted fat-loss" peptide. The actual clinical evidence is mixed, regulatory status is non-existent, and the marketing claims outrun the data substantially. Honest evidence review.

May 11, 2026 · 7 min readRead →

Peptide Education

How to Spot Unsafe Peptide Sources (And What Happens If You Use Them)

A practical guide to red flags in peptide sourcing — research-only labels, no prescription, anonymous suppliers — and what contamination actually does.

May 11, 2026 · 10 min readRead →

Peptide Education

Are Peptides Safe? An Honest 2026 Assessment

A clinical, class-by-class look at peptide safety — GLP-1, GHRH, NAD+, BPC-157 — and why sourcing and oversight matter as much as the molecule.

May 10, 2026 · 8 min readRead →

Peptide Education

Peptide Therapy Contraindications You Should Know

A clinical map of who should not be on peptide therapy — pregnancy, malignancy, endocrine syndromes, and class-specific exclusions a clinician screens for.

May 10, 2026 · 8 min readRead →

Peptide Education

BPC-157: Regulatory Status and Clinical Research Pipeline

Current legal status, FDA position, ongoing trials, and what the actual evidence says about the healing and recovery claims around BPC-157 in 2026.

May 9, 2026 · 9 min readRead →

Peptide Education

PT-141 (Bremelanotide): What's New for Sexual Health Peptides in 2026

Melanocortin mechanism vs PDE5 inhibitors, FDA-approval status, off-label use in men, telehealth prescribing, side effects, and contraindications.

May 9, 2026 · 8 min readRead →

Peptide Education

Retatrutide: The Triple-Agonist GLP-1/GIP/GCG (2026 Update)

Phase 3 status, mechanism vs current GLP-1s, expected approval timeline, and what triple-agonism actually changes about weight-loss pharmacology.

May 9, 2026 · 8 min readRead →

Peptide Education

Sermorelin Side Effects: What to Watch For

Injection-site reactions, vivid dreams, headache, and the contraindications that disqualify a candidate. A clinical look at sermorelin tolerability.

May 9, 2026 · 7 min readRead →

Peptide Education

12 New Peptides Coming Soon: The 2026–2028 Pipeline Watchlist

A complete watchlist of the 12 most consequential peptides in late-stage development through 2028 — mechanism, sponsor, expected approval window, and what each one would change.

May 8, 2026 · 8 min readRead →

Peptide Education

Compounded Retatrutide, MariTide, and Investigational Peptides: Why They Are Not Legitimate

Compounded versions of investigational peptides — retatrutide, MariTide, mazdutide, pemvidutide, others — are not the investigational drugs. What is actually being sold, why it is not legitimate, and the regulatory framework that explains it.

May 8, 2026 · 9 min readRead →

Peptide Education

GLP-1 Plateau: What It Means and Your Options Through 2028

A clinical look at the GLP-1 plateau — why weight loss slows after months of therapy, what to do about it now, and how the 12 new peptides on the late-stage pipeline change the conversation.

May 8, 2026 · 9 min readRead →

Peptide Education

MariTide (Maridebart Cafraglutide): The Monthly GLP-1 Antibody-Conjugate (2026 Update)

MariTide is Amgen's peptide-antibody conjugate combining GLP-1 agonism with GIP antagonism, dosed monthly. Mechanism, trial status, and how monthly dosing changes the patient experience.

May 8, 2026 · 8 min readRead →

Peptide Education

Mazdutide: GLP-1/Glucagon Dual Agonist in Late-Stage Trials (2026 Update)

Mazdutide is a dual GLP-1/glucagon agonist co-developed by Innovent and Eli Lilly, with Phase 3 readouts in obesity and metabolic disease. Mechanism, trial status, and approval timeline.

May 8, 2026 · 7 min readRead →

Peptide Education

Orforglipron: The First True Oral GLP-1 Pill (2026 Update)

Orforglipron is a small-molecule oral GLP-1 in late-stage trials. Mechanism, phase 3 readouts, expected approval timing, and what an oral GLP-1 actually changes for patients.

May 8, 2026 · 8 min readRead →

Peptide Education

Pemvidutide: GLP-1/Glucagon for MASH and Obesity (2026 Update)

Pemvidutide is Altimmune's GLP-1/glucagon dual agonist with a focus on MASH and obesity. Phase 2 data, ongoing trials, and what differentiates it in the dual-agonist class.

May 8, 2026 · 6 min readRead →

Peptide Education

Petrelintide: The Long-Acting Amylin Analog (2026 Update)

Petrelintide is Zealand Pharma's long-acting amylin analog in late-stage trials. Mechanism, weight-loss efficacy, and how amylin pharmacology differs from GLP-1.

May 8, 2026 · 7 min readRead →

Peptide Education

Sermorelin Dosing: Timing, Cycles, and Titration

How clinicians titrate sermorelin: weight-based starting doses, evening timing rationale, cycle length, and the dose-adjustment signals that matter.

May 8, 2026 · 6 min readRead →

Peptide Education

Sermorelin: How GHRH Mimics Stimulate Natural Growth Hormone

Sermorelin mimics GHRH at the pituitary, restoring pulsatile growth hormone release. Why this is structurally safer than synthetic HGH, with the clinical evidence.

May 8, 2026 · 6 min readRead →

Peptide Education

Sermorelin vs CJC-1295 vs Ipamorelin: Mechanism Differences

Three peptides, three different receptor strategies. The clinical case for each — half-lives, receptor targets, stack interactions, and when each is preferred.

May 8, 2026 · 7 min readRead →

Peptide Education

NAD+ Side Effects: An Honest Look at What to Expect

NAD+ side effects, dose-dependent reactions, and contraindications — a clinical assessment of what to expect on prescribed NAD+ therapy and when to stop.

May 7, 2026 · 7 min readRead →

Peptide Education

NAD+ Injection Routes Compared: Subcutaneous, IV, and IM

NAD+ injection routes compared on bioavailability, dosing, side effects, and clinical fit. Why prescribed subcutaneous NAD+ has become the default for at-home protocols.

May 6, 2026 · 7 min readRead →

Peptide Education

NAD+ vs NMN vs NR: Which Precursor Actually Reaches Your Cells

NAD+ vs NMN vs NR — bioavailability, conversion pathways, and why prescribed subcutaneous NAD+ outperforms oral precursors on a per-effective-dose basis.

May 6, 2026 · 7 min readRead →

Peptide Education

Prescribed Peptides vs "Research-Only" Peptides: The Critical Distinction

Why "for research purposes only" peptides are not a budget version of prescribed therapy — the legal posture, real risks, and contamination history that separate them.

May 6, 2026 · 13 min readRead →

Peptide Education

Compounded vs FDA-Approved Peptides: The Difference Explained

A precise explanation of compounded vs FDA-approved peptides, including 503A vs 503B compounding, quality control, and what the FDA actually says.

May 5, 2026 · 12 min readRead →

Peptide Education

Which Peptides Are Actually FDA-Approved (The 2026 Real List)

The actual list of FDA-approved peptide drugs in 2026, with indications, sponsors, and how compounded peptides legally fit alongside them.

May 5, 2026 · 10 min readRead →

Compliance

All clinical posts on this blog are medically reviewed before publication. Compounded medications referenced here are prepared by licensed 503A pharmacies. Compounded medications are not FDA-approved. Prescribing decisions are made solely by licensed clinicians based on individual medical necessity. These statements have not been evaluated by the FDA.